Revelation Biosciences Inc (REVB) 시세

REVB, new 52 week low

$REVB 4.35

$REVB 4.18

REVB those engines $1 + 111%

revb...........................https://stockcharts.com/h-sc/ui?s=revb&p=W&b=5&g=0&id=p86431144783

Sneaking up today .51

REVB...........................https://stockcharts.com/h-sc/ui?s=REVB&p=W&b=5&g=0&id=p86431144783

REVB, new 52 week low

REVB BLAST INTO CLOSE

FDA clearance .85

REVB.................................https://stockcharts.com/h-sc/ui?s=REVB&p=W&b=5&g=0&id=p86431144783

Nice bump..+ 20% $1.07..
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024November 08 2024 - 4:15PM
Business WireRevelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results.Corporate HighlightsCompleted GMP manufacture of Gemini clinical drug supplyReceived net proceeds of $3.8 million from the exercise of warrants in August 2024Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers“The Revelation team continues to make significant progress on the advancement of Gemini,” said James Rolke, Chief Executive Officer of Revelation. “We look forward to the anticipated acceptance of our IND by the FDA and building on this momentum with the start of our Phase 1b study in CKD patients in the United States.”Results of OperationsAs of September 30, 2024, Revelation had $6.5 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The decrease in cash and cash equivalents was primarily due to cash used for operating activities and the Lifesci Capital judgment, offset by net cash received from financing activities. Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations into 2025.Revelation’s net cash used for operating activities for the nine months ended September 30, 2024 was $14.6 million compared to net cash used for operating activities of $5.3 million for the same period in 2023. Revelation’s net loss for the three months ended September 30, 2024 was $2.2 million, or $0.84 basic and diluted net loss per share compared to a net loss of $2.6 million, or $9.94 basic and diluted net loss per share for the same period in 2023. Revelation’s net loss for the nine months ended September 30, 2024 was $13.3 million, or $7.38 basic and diluted net loss per share compared to net income of $2.1 million, or $9.62 basic net earnings per share and $9.38 diluted net earnings per share for the same period in 2023, respectively.About GeminiGemini is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®) for systemic administration. It is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program), and as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program). In addition, Gemini may be a treatment to stop or slow the progression of chronic kidney disease (GEMINI-CKD program). Revelation believes Gemini works through trained immunity, which redirects and attenuates the innate immune response to external stress (infection, trauma, etc.). Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications.About Revelation Biosciences, Inc.Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.

REVB......................................https://stockcharts.com/h-sc/ui?s=REVB&p=W&b=5&g=0&id=p86431144783

REVB new 52 week low

REVB under $2

REVB........................https://stockcharts.com/h-sc/ui?s=REVB&p=W&b=5&g=0&id=p86431144783

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

REVBW: Are ya all READY for the greatest stock price EXPLOSION in the entire history of WALL STREET!!! (Second only to the legendary @HKD run-up, the iHub board for which I myself created!!!)


WIFE: "Oh--my-God, Tom!!! Was that the Russian Satan-II Bomb going off here in our wonderful San Diego, California, US NAVY Fleet Harbor???!!!"
HUBBY: "Fret not, Honey --- it was just the explosion in the PRICE our REVB stock WARRANTS."
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

REVB..........................https://stockcharts.com/h-sc/ui?s=REVB&p=W&b=5&g=0&id=p86431144783

REVB: Whoops, the MONKSTER did it again!! (See him below in action, LIVE right now!!!)


"Oh-my-God!!! I see a 52-YEAR low for my LOVE LIFE --- approaching in precisely 6-DAYS!!!"
//////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

PRE MKT SIZZLE!

REVB new 52=w e ek low

REVB new 52 week low

REVB new 52 week low

REVB under $2

REVB under $2

Whoops, I did it, again

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

REVB new 52 low

REVB new 52=week low

is this ever going to move?..up?

Added more 2.80s here like chart longer term have to start somewhere

https://stockcharts.com/h-sc/ui?s=REVB

5-10$ tm weeeer

Covering into close

Going to moon here picked up 5k low 3s

REVB new 52 week low

MDVL Wow Stocks Down -60% on 9k Volume dont see any news

REVB new 52 week low

25 bucks to 3 bucks. Don’t blink

Covered REVB short position!

REVB 66$ Cash Per Share Trading at 7.60$ Trading nearly 60$ Per share Under Cash 175K Float total shares outstanding is 210k Market cap 1.5 Million VS Cash 14 Million in Cash https://finance.yahoo.com/quote/REVB/key-statistics?p=REVB

REVB: Touche, Girl!!! (NOBODY can out-wit Her Majesty, Empress-CJ-The-Second!!! (GOOD LUCK though, with your MGRX --- you will NEED it to get its price UP --- no pun intended!!)

$REVB needs some MGRX 🥭

REVB: And then, "The-Hot-Dog-Fell-Off-The-Mustard"!!!

https://stockcharts.com/h-sc/ui?s=revb&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/revb/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100

https://www.barchart.com/stocks/quotes/revb/opinion

https://finance.yahoo.com/quote/revb/

Short setup with REVB!

Oh babes!!!

Looks like already hit 23 pre market.

REVB 175K Float With 66$+ Cash Per Share Trading at 16$ https://finance.yahoo.com/quote/REVB/key-statistics?p=REVB

Thank you..

Looks like you're going to be right